Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.35 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.30 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23974015 | 0.81 | HRH3 (0.35) | HRH3 | |
| SCHEMBL13644716 | 0.81 | HRH3 (0.35) | HRH3 | |
| SCHEMBL4410585 | 0.75 | HRH3 (0.38) | HRH3ITGB3ITGA2B | |
| SCHEMBL12334338 | 0.75 | HRH3 (0.38) | HRH3ITGB3ITGA2B | |
| SCHEMBL4402037 | 0.75 | HRH3 (0.38) | HRH3ITGB3ITGA2B | |
| SCHEMBL17966443 | 0.74 | ITGB3 (0.39) | HRH3ITGB3ITGA2B | |
| SCHEMBL417814 | 0.74 | HRH3 (0.37) | HRH3ITGB3ITGA2B | |
| SCHEMBL6948618 | 0.74 | HRH3 (0.37) | HRH3ITGB3ITGA2B | |
| SCHEMBL31420767 | 0.74 | HRH3 (0.37) | HRH3ITGB3ITGA2B | |
| SCHEMBL10417796 | 0.74 | ITGB3 (0.39) | HRH3ITGB3ITGA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2721019-B1 | THERAPEUTICALLY ACTIVE COMPOSITIONS AND THEIR METHODS OF USE | AGIOS PHARMACEUTICALS INC (US) | 2018-08-08 | — | — | EP | disclosed |
| EP-2721019-B1 | THERAPEUTICALLY ACTIVE COMPOSITIONS AND THEIR METHODS OF USE | AGIOS PHARMACEUTICALS INC (US) | 2018-08-08 | — | — | EP | disclosed |
| US-9856279-B2 | Therapeutically active compositions and their methods of use | AGIOS PHARMACEUTICALS, INC. (US) | 2018-01-02 | — | — | US | disclosed |
| US-9856279-B2 | Therapeutically active compositions and their methods of use | AGIOS PHARMACEUTICALS, INC. (US) | 2018-01-02 | — | — | US | disclosed |
| US-20170210749-A1 | THERAPEUTICALLY ACTIVE COMPOSITIONS AND THEIR METHODS OF USE | SERVIER PHARMACEUTICALS LLC | 2017-07-27 | — | — | US | disclosed |
| US-20170210749-A1 | THERAPEUTICALLY ACTIVE COMPOSITIONS AND THEIR METHODS OF USE | SERVIER PHARMACEUTICALS LLC | 2017-07-27 | — | — | US | disclosed |
| US-9662327-B2 | Phenyl and pyridinyl substituted piperidines and piperazines as inhibitors of IDH1 mutants and their use in treating cancer | AGIOS PHARMACEUTICALS, INC (US) | 2017-05-30 | — | — | US | disclosed |
| US-9662327-B2 | Phenyl and pyridinyl substituted piperidines and piperazines as inhibitors of IDH1 mutants and their use in treating cancer | AGIOS PHARMACEUTICALS, INC (US) | 2017-05-30 | — | — | US | disclosed |
| EP-2721033-B1 | COMPOUNDS, THEIR PHARMACEUTICAL COMPOSITIONS AND THEIR USES AS IDH1 MUTANTS INHIBITORS FOR TREATING CANCERS | AGIOS PHARMACEUTICALS INC (US) | 2016-12-07 | — | — | EP | disclosed |
| US-20160229876-A1 | THERAPEUTICALLY ACTIVE COMPOSITIONS AND THEIR METHODS OF USE | SERVIER PHARMACEUTICALS LLC | 2016-08-11 | — | — | US | disclosed |
| US-20160229876-A1 | THERAPEUTICALLY ACTIVE COMPOSITIONS AND THEIR METHODS OF USE | SERVIER PHARMACEUTICALS LLC | 2016-08-11 | — | — | US | disclosed |
| US-20140213580-A1 | THERAPEUTICALLY ACTIVE COMPOSITIONS AND THEIR METHODS OF USE | AGIOS PHARMACEUTICALS, INC (US) | 2014-07-31 | — | — | US | disclosed |
| US-20140206673-A1 | THERAPEUTICALLY ACTIVE COMPOSITIONS AND THEIR METHODS OF USE | AGIOS PHARMACEUTICALS, INC (US) | 2014-07-24 | — | — | US | disclosed |
| US-20140206673-A1 | THERAPEUTICALLY ACTIVE COMPOSITIONS AND THEIR METHODS OF USE | AGIOS PHARMACEUTICALS, INC (US) | 2014-07-24 | — | — | US | disclosed |
| EP-2721019-A1 | THERAPEUTICALLY ACTIVE COMPOSITIONS AND THEIR METHODS OF USE | Agios Pharmaceuticals, Inc. (US) | 2014-04-23 | — | — | EP | disclosed |
| EP-2721033-A1 | COMPOUNDS, THEIR PHARMACEUTICAL COMPOSITIONS AND THEIR USES AS IDH1 MUTANTS INHIBITORS FOR TREATING CANCERS | Agios Pharmaceuticals, Inc. (US) | 2014-04-23 | — | — | EP | disclosed |
| WO-2012171506-A1 | COMPOUNDS, THEIR PHARMACEUTICAL COMPOSITIONS AND THEIR USES AS IDH1 MUTANTS INHIBITORS FOR TREATING CANCERS | AGIOS PHARMACEUTICALS, INC. (US) | 2012-12-20 | — | — | WO | disclosed |
| WO-2012171337-A1 | THERAPEUTICALLY ACTIVE COMPOSITIONS AND THEIR METHODS OF USE | AGIOS PHARMACEUTICALS, INC. (US) | 2012-12-20 | — | — | WO | disclosed |
| WO-2012171337-A1 | THERAPEUTICALLY ACTIVE COMPOSITIONS AND THEIR METHODS OF USE | AGIOS PHARMACEUTICALS, INC. (US) | 2012-12-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170210749-A1 | THERAPEUTICALLY ACTIVE COMPOSITIONS AND THEIR METHODS OF USE | RNASE1, GZMB, ANXA2 | HRH3 2034/4885ITGB3 864/4885ITGA2B 1171/4885 |
| US-20140206673-A1 | THERAPEUTICALLY ACTIVE COMPOSITIONS AND THEIR METHODS OF USE | RNASE1, GZMB, ANXA2 | HRH3 2034/4885ITGB3 864/4885ITGA2B 1171/4885 |
| US-20140213580-A1 | THERAPEUTICALLY ACTIVE COMPOSITIONS AND THEIR METHODS OF USE | RNASE1, TP53, MCL1 | HRH3 4052/4885ITGB3 1252/4885ITGA2B 1257/4885 |
| US-20160229876-A1 | THERAPEUTICALLY ACTIVE COMPOSITIONS AND THEIR METHODS OF USE | MCL1, TP53, MMP8 | HRH3 3631/4885ITGB3 1296/4885ITGA2B 1587/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.